HistoSonics, the developer of the Edison® Histotripsy System, announced today that Elevance Health (formerly Anthem, Inc.) has issued a positive medical policy for the use of histotripsy in the treatment of liver tumors. The policy, effective October 21, 2025, expands coverage across Elevance Health’s commercial, Medicare, and Medicaid plans in 14 states, including California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, and Wisconsin, broadening access to the incisionless, non‑thermal therapy for approximately 45.4 million members.
The coverage expansion applies to all three of Elevance Health’s core plan types—commercial, Medicare Advantage, and Medicaid—providing a uniform benefit for patients with liver tumors in the covered states. By adding histotripsy to its formulary, Elevance Health is positioning itself to support a growing class of minimally invasive treatments that can reduce complications and recovery times for patients. The policy’s effective date of October 21, 2025 means that members can begin receiving the therapy immediately under the new benefit.
This announcement is significant for Elevance Health because it expands the insurer’s portfolio of innovative, high‑value therapies and increases the potential for utilization among its 45.4 million members. The addition of a FDA‑approved, non‑thermal, incisionless treatment aligns with the company’s strategy to enhance member experience and differentiate its health plans in a competitive market. The move also signals Elevance Health’s commitment to adopting emerging medical technologies that can improve outcomes and potentially reduce long‑term costs for its members.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.